Fore

Fore Genomics Adopts DNAnexus Platform to Access and Analyze Whole-Genome Newborn Screening Data

Retrieved on: 
Tuesday, July 25, 2023
Data Management, Other Health, Technology, Pharmaceutical, General Health, Professional Services, Genetics, Baby, Maternity, Biotechnology, Science, Software, Other Science, Consumer, Data Analytics, Research, Health, NIST, Genetic variation, DNA, Genomics, Parent, ISO27001, Privacy, Risk, Map, Genetic testing, GDPR, Fore, DNAnexus, Gene, Disease, Antibiotics

DNAnexus Inc., the leading provider of cloud-based genomic and biomedical data access and companion analysis software, today announced that Fore Genomics, a proactive genetic testing company designed for healthy newborns, infants, and children, is using the DNAnexus platform for its FORESITE 360 test.

Key Points: 
  • DNAnexus Inc., the leading provider of cloud-based genomic and biomedical data access and companion analysis software, today announced that Fore Genomics, a proactive genetic testing company designed for healthy newborns, infants, and children, is using the DNAnexus platform for its FORESITE 360 test.
  • The purpose-built and scalable DNAnexus platform enables Fore Genomics to meet with current and future security, quality, and compliance requirements as they evolve over time.
  • The FORESITE 360 test is a groundbreaking health information service that creates a complete genomic profile using a baby’s DNA.
  • “Protecting our customer data is paramount to what we do, and DNAnexus offers the industry's most stringent security, privacy, and compliance platform.

J.F. Lehman & Company Announces New Hires

Retrieved on: 
Monday, April 24, 2023
Kardan University, Senior, Average revenue per user, Internal Revenue Service, Head, New York University School of Law, University School, In-Q-Tel, Millennium Management, LLC, Certified Public Accountant, Investment, U.S. Department of Defense Strategy for Operating in Cyberspace, Comptroller, University, Government, Morgan Stanley, White House, Culture, Cowen Inc., Cravath, Swaine & Moore, Research, Golden Gate Capital, Primary energy, Organization, Partner, Standard Chartered, Paris, Growth, Lafayette College, Airbus, LLP, Cravath, Business, Record, Dartmouth College, Modern Institute of Technology and Management, White, M.B.A, Engineering, Secrecy, Weil, Gotshal & Manges, Intelligence, Marketing, Tuck School of Business, Fore, Security (finance), Nursing, New York University, Finance

Lehman & Company ("JFLCO"), a leading middle-market private equity firm focused exclusively on the aerospace, defense, maritime, government and environmental industries, is pleased to announce several new hires.

Key Points: 
  • Lehman & Company ("JFLCO"), a leading middle-market private equity firm focused exclusively on the aerospace, defense, maritime, government and environmental industries, is pleased to announce several new hires.
  • "The addition of these talented individuals is expected to enhance our transaction sourcing and execution capabilities and other business processes."
  • Mr. Lederman has chaired various creditor committees in large and complex restructurings and served on numerous public and private corporate boards, including currently serving as a director on JFLCO portfolio company, PURIS.
  • A native of New York, Mr. Lederman graduated magna cum laude from New York University, where he earned a B.A.

J.F. Lehman & Company Announces New Hires

Retrieved on: 
Monday, April 24, 2023
Kardan University, Senior, Average revenue per user, Internal Revenue Service, Head, New York University School of Law, University School, In-Q-Tel, Millennium Management, LLC, Certified Public Accountant, Investment, U.S. Department of Defense Strategy for Operating in Cyberspace, Comptroller, University, Government, Morgan Stanley, White House, Culture, Cowen Inc., Cravath, Swaine & Moore, Research, Golden Gate Capital, Primary energy, Organization, Partner, Standard Chartered, Paris, Growth, Lafayette College, Airbus, LLP, Cravath, Business, Record, Dartmouth College, Modern Institute of Technology and Management, White, M.B.A, Engineering, Secrecy, Weil, Gotshal & Manges, Intelligence, Marketing, Tuck School of Business, Fore, Security (finance), Nursing, New York University, Finance

Lehman & Company ("JFLCO"), a leading middle-market private equity firm focused exclusively on the aerospace, defense, maritime, government and environmental industries, is pleased to announce several new hires.

Key Points: 
  • Lehman & Company ("JFLCO"), a leading middle-market private equity firm focused exclusively on the aerospace, defense, maritime, government and environmental industries, is pleased to announce several new hires.
  • "The addition of these talented individuals is expected to enhance our transaction sourcing and execution capabilities and other business processes."
  • Mr. Lederman has chaired various creditor committees in large and complex restructurings and served on numerous public and private corporate boards, including currently serving as a director on JFLCO portfolio company, PURIS.
  • A native of New York, Mr. Lederman graduated magna cum laude from New York University, where he earned a B.A.

Golden Grail Beverages (OTC:GOGY) Donates Cause Water in Celebration of Earth Day

Retrieved on: 
Monday, April 24, 2023
Stroud Water Research Center, Education, Grolla d'oro, Golf, Fresh water, Water, OTC, Fore, Environment

FORT LAUDERDALE, Fla., April 24, 2023 /PRNewswire/ -- Golden Grail Technology, doing business as Golden Grail Beverages (OTC: GOGY), In observance of Earth Day is proud to announce its donation of Cause Water in support of the Stroud™ Water Research Center's upcoming Fore Fresh Water Golf Invitational.

Key Points: 
  • FORT LAUDERDALE, Fla., April 24, 2023 /PRNewswire/ -- Golden Grail Technology, doing business as Golden Grail Beverages (OTC: GOGY), In observance of Earth Day is proud to announce its donation of Cause Water in support of the Stroud™ Water Research Center's upcoming Fore Fresh Water Golf Invitational.
  • The collaboration between Golden Grail Beverages and Stroud™ Water Research Center demonstrates a shared passion for preserving our planet's most precious resource—water.
  • Cause Water is an environmentally friendly, pure mountain spring water bottled at the source in a premium recyclable can with a resealable cap.
  • "We are thrilled to pair Cause Water's goal to reduce plastic pollution for a cleaner environment together with Stroud™ Water Research Center's mission for freshwater research, education, and restoration," said Steven Hoffman, CEO of Golden Grail.

Micro-Electromechanical Systems (MEMS) Global Market to Reach $22.6 Billion by 2030: Increasing Spending on Industrial Automation Initiatives to Boost Market Prospects

Retrieved on: 
Tuesday, April 11, 2023
Real, Smart, Race, Virus, Service robot, Internet of things, Electronics, Automotive industry, US, Growth, Big data, Fore, Consumer electronics, Automotive Electronics Council, Video game, Pet industry

As the Race between the Virus & Vaccines Intensifies, Where is the World Economy Headed in 2021?

Key Points: 
  • As the Race between the Virus & Vaccines Intensifies, Where is the World Economy Headed in 2021?
  • World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
    Global PMI Index Points for the Years 2018, 2019 & 2020
    Major Industry 4.0 Technologies: Global Market Size (US$ Billion) for Internet of Things (IoT), Big Data, Smart Factory, Advanced Analytics, Service Robotics, and Smart Machines for 2020
    Automotive Electronics as a Percentage (%) of Vehicle Production Cost for the Years 2010, 2020 & 2030
    Average Value of In-Vehicle Electronics Per Vehicle (In US$) for the Years 2018, 2025 & 2030
    World Automobile Production in Million Units: 2008-2022
    Sustained Growth of Automotive Sensors: Opportunity for MEMS Market
    As Autonomous Vehicles Come to the Fore, MEMS Market Poised to Benefit
    Global Autonomous Vehicle Sales (In Million) for Years 2020, 2025 & 2030
    Global Opportunity for Consumer Electronics (In US$ Million) for Years 2020, 2022, 2024, 2026 and 2028
    Global Market for Smartphones in Billions: 2016-2021
    Smartphone Penetration Rate as Share of Total Population: 2016-2021
    Global Smart Homes Market (In US$ Billion) for the Years 2019, 2021, 2023 & 2025

FORE Biotherapeutics Receives FDA Orphan Drug Designation for FORE8394 for the Treatment of Primary Brain and CNS Malignancies

Retrieved on: 
Monday, March 20, 2023
Neurology, Biotechnology, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Other Health, China Biologic Products, Central nervous system, Drug development, ODD, Neoplasm, ESMO, Cancer, BRAF, Genomics, CNS, Trial of the century, V600, Malignancy, Patient, FORTE, Fore, Rare, European Society for Medical Oncology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Food, RAF, Pharmaceutical industry

FORE Biotherapeutics (FORE Bio) a precision stage oncology company dedicated to developing innovative treatments that provide a better outcome for cancer patients announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead program, FORE8394, for the treatment of primary brain and central nervous system (CNS) malignancies.

Key Points: 
  • FORE Biotherapeutics (FORE Bio) a precision stage oncology company dedicated to developing innovative treatments that provide a better outcome for cancer patients announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead program, FORE8394, for the treatment of primary brain and central nervous system (CNS) malignancies.
  • This is the first orphan drug designation received by FORE Bio and the FORE8394 program.
  • "The receipt of Orphan Drug Designation is another important regulatory achievement that reinforces the FDA's recognition of the potential of FORE8394 to improve clinical outcomes in patients with BRAF-altered brain tumors,” said Stacie Shepherd, M.D., Ph.D., Chief Medical Officer of Fore Biotherapeutics.
  • Orphan Drug Designation is granted to drugs or biological products for the treatment of rare diseases or conditions that impact fewer than 200,000 people in the United States.

Photonic Integrated Circuit (PIC) Global Market Report 2023: Expanding Role of DCI in Data Centers Creates Potential Market Opportunities

Retrieved on: 
Saturday, March 4, 2023
DCI, Fore, Equipment, Monolith, Engineer, Scalability

Data Center Interconnect (DCI) Related Needs of Enterprises by Sector: A Snapshot

Key Points: 
  • Data Center Interconnect (DCI) Related Needs of Enterprises by Sector: A Snapshot
    Global Data Center Traffic Scenario (2018, 2020 & 2022E): Percentage Breakdown of Data Center Traffic by Equipment Type
    Growing Bandwidth Needs Bring Fiber Optic Networks to the Fore, Steering PIC Demand
    Global Smart Homes Market (In US$ Billion) for the Years 2019, 2021, 2023 & 2025E
    A Monolithic InP-on-Si-on-Insulator Developed by a HKUST Team of Engineers.
  • Optoscribe Begins Sampling its New PIC Coupling Solution, OptoCplrLT
    Purdue University Research Team Develops an Electrically Driven, Magnetic-Free Linear Optical Isolator for PIC Production
    Next Generation Silicon Photonics & Polymer Based Photonic ICs Enhance Speed, Bandwidth and Scalability

Fore Biotherapeutics Announces Fast Track Designation Granted by FDA to FORE8394 for the Treatment of Cancers Harboring BRAF Class 1 and Class 2 Alterations

Retrieved on: 
Wednesday, September 28, 2022
Biotechnology, FDA, Health, Pharmaceutical, Oncology, Central nervous system, Safety, Accelerated approval (FDA), FTD, Twitter, V600, FDA, Food, Neoplasm, LinkedIn, European Society for Medical Oncology, Review, BRAF, Program, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cancer, Fore, White Light Rock & Roll Review, Fast Track, Priority review, Drug development, CNS, Genomics, RAF, ESMO, Pharmaceutical industry

The FDA's Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.

Key Points: 
  • The FDA's Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.
  • A drug that receives Fast Track designation may become eligible for Accelerated Approval, Priority Review, or Rolling Review if relevant criteria are met.
  • The FDA's Fast Track Designation for FORE8394 underscores the urgent need faced by patients with advanced BRAF-muted cancers who have no other options, said Stacie Shepherd, M.D., Ph.D., Chief Medical Officer of Fore Biotherapeutics.
  • We look forward to continuing to work closely with the FDA as we explore the potential for FORE8394 to improve outcomes for patients with these life-threatening cancers.

Fore Biotherapeutics Presents Positive Interim Data From Phase 1/2a Trial Evaluating FORE8394 in Patients With Advanced Tumors With Activating BRAF Alterations at ESMO 2022

Retrieved on: 
Monday, September 12, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Adult, Glioma, Phase II, Papillary thyroid cancer, Central nervous system, Safety, MAPK, Twitter, MD, Diarrhea, Ovarian cancer, Neoplasm, Colorectal cancer, LinkedIn, European Society for Medical Oncology, CRC, BRAF, Cobicistat, Patient, AES, Cancer, Fore, ORR, Doctor of Philosophy, Drug development, CNS, Genomics, Nausea, Fatigue, Memorial Sloan Kettering Cancer Center, PFS, HIV disease progression rates, CYP3A4, PR, RAF, ESMO, Pharmaceutical industry, Medical imaging

"These results are very encouraging and reinforce our conviction that FORE8394 has the potential to provide meaningful benefit to patients with BRAF-mutated cancers with high unmet need.

Key Points: 
  • "These results are very encouraging and reinforce our conviction that FORE8394 has the potential to provide meaningful benefit to patients with BRAF-mutated cancers with high unmet need.
  • We are embarking upon developing this novel treatment and are on track to initiate our global Phase 2 trial next quarter.
  • "We're excited that the majority of gliomas demonstrated response and the prolonged benefit and tolerability experienced by some patients receiving FORE8394.
  • Fore Bio is a precision oncology company dedicated to developing innovative treatments that provide a better outcome for cancer patients.

Fore Biotherapeutics to Present Phase 1/2a Data on FORE8394, a Next-Generation BRAF Inhibitor, at ESMO 2022

Retrieved on: 
Tuesday, August 9, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Genomics, ESMO, RAF, CNS, European Society for Medical Oncology, Fore, Cancer, Neoplasm, Patient, Twitter, Development of the human body, Safety, Drug development, BRAF, V600, LinkedIn, Pharmaceutical industry

The Phase 1/2a open-label study is assessing FORE8394, a next-generation BRAF inhibitor, in patients with advanced solid and CNS tumors with activating BRAF alterations.

Key Points: 
  • The Phase 1/2a open-label study is assessing FORE8394, a next-generation BRAF inhibitor, in patients with advanced solid and CNS tumors with activating BRAF alterations.
  • Details for the presentation are as follows:
    FORE8394 is an investigational, novel, small-molecule, next-generation, orally available selective inhibitor of mutated BRAF.
  • It was designed to target a wide range of BRAF mutations while sparing wild type forms of RAF.
  • Lead asset FORE8394 is a Class I/II BRAF inhibitor with demonstrated clinical safety and early efficacy signals in an ongoing Phase 1/2a clinical trial.